Food, Drugs, and Cosmetics - Gene Structure- and Function-Modifying Products - Labeling
If enacted, SB124 will significantly alter existing state laws regarding food and drug labeling. It will create a new regulatory framework under the health codes for labeling products that employ advanced biotechnological processes. Any violation of these labeling requirements can result in considerable penalties, including fines and imprisonment, thereby serving as a deterrent against non-compliance. This move is aimed at protecting consumers from possibly unregulated or poorly understood products that may pose health risks due to their genetic modifications.
Senate Bill 124, titled 'Food, Drugs, and Cosmetics - Gene Structure- and Function-Modifying Products - Labeling', aims to regulate the sale of gene structure- or function-modifying products within the state. The bill specifically prohibits any such products from being offered for sale unless they are properly labeled to inform consumers about their nature. This includes clear indications that a product is gene structure- or function-modifying as well as disclosures of potential risks and side effects associated with the use of these products. The intent behind this legislation is to enhance consumer safety and transparency in a market increasingly influenced by modern biotechnology methods such as gene editing and transgenesis.
While the bill is positioned as a consumer protection measure, it may stir contention among stakeholders in the biotechnology and agricultural sectors. Proponents of the bill argue that stringent labeling will empower consumers to make informed choices. However, critics may view the legislation as overly burdensome, potentially stifling innovation in biotechnology and increasing costs for manufacturers. Additionally, there could be concerns regarding how the labeling requirements may affect marketability and consumer perceptions of gene-modified products.